

# A study of adjuvant chemotherapy for malignant glioma

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 12/04/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

[http://www.ctu.mrc.ac.uk/research\\_areas/study\\_details.aspx?s=101](http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=101)

## Contact information

### Type(s)

Scientific

### Contact name

Dr Hannah Brooks

### Contact details

MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

### Protocol serial number

BR05

## Study information

### Scientific Title

### Study objectives

To assess whether the addition of chemotherapy to a standard radiotherapy regime influences the survival of adult patients with malignant glioma (astrocytomas grades 3 & 4) and to assess the ability of in vitro chemosensitivity testing to identify patients with a better prognosis.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Cancer

**Interventions**

1. One group receives chemotherapy added to a standard radiotherapy regimen
2. The other group receives none

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Chemotherapy

**Primary outcome(s)**

Survival time

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

30/06/1996

**Eligibility****Key inclusion criteria**

1. Age 18-69
2. No previous treatment except surgery, corticosteroids, anticonvulsants or diuretics

3. Entry within 6 weeks of surgery
4. Other malignancies
5. Fitness for treatment

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

69 years

**Sex**

All

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/09/1988

**Date of final enrolment**

30/06/1996

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

**Sponsor information**

## Organisation

Medical Research Council (MRC) (UK)

## Funder(s)

### Funder type

Research council

### Funder Name

Medical Research Council (MRC) (UK)

### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	15/01/2001		Yes	No